Carcinoma is a leading cause of cancer-related death in women with over 12,000 new cases and 4,000 deaths in the United States annually.12

Advanced recurrent/peristent and metastatic forms of cervical cancer have poor outcomes with mean progression free survival (PFS) rates less than 8 months following standard platinum-based chemotherapy with post-progression overall survival of 8.4 mos when bevacizumab is added.14

ORR in patients who failed platinum-containing regimens is 11-24% with short durations (5-3 mos).15

The presence of tumor-infiltrating lymphocytes (TIL) has been well documented in patients with human papillomavirus (HPV)-associated cancers, including cervical cancer, and have been positively correlated with improved patient outcomes.16,17

Several early studies have demonstrated the feasibility of isolation and culture of TIL from cervical tumors.18,12

A pilot study of TIL therapy in 9 patients with previously treated cervical carcinomas demonstrated an ORR of 33% that included 2 durable long-term (46 and 54 mos) responses.15

This study was designed to evaluate the efficacy and safety of LN-145, an autologous investigational TIL therapy for the treatment of patients with recurrent, metastatic, or persistent cervical carcinomas.

**STUDY OBJECTIVES**

Primary:
- To evaluate the efficacy of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinomas using the objective response rate (ORR).

Secondary:
- To characterize the safety profile of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinomas.
- To evaluate efficacy of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinomas such as complete response (CR) rate, duration of response (DOR), disease control rate (DCR), and progression-free survival (PFS), & overall survival (OS).

Exploratory:
- To explore the persistence of LN-145 and immune correlates of response, survival, toxicity of the treatment.
- To explore efficacy based on immune-related RECIST (iRECIST) as assessed by independent review.
- To assess health-related quality of life (HRQoL).
- To assess quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWIST).

**STUDY OVERVIEW**

- **C-145-0-0 (NCT03108495)** is a Phase 2, multicenter prospective, open label, interventional study designed to evaluate adaptive cell therapy (ACT) with autologous TIL infusion (LN-145) followed by IL-2 after a non-myeloblastic (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical cancer who were unresponsive to or failing prior therapy.

- All squamous cell carcinomas, adenocarcinomas, adenosquamous pathologies will be enrolled regardless of prior treatment.

- Up to 40 clinical study sites globally

- The planned sample size, N = 47 treated patients

**STUDY FLOWCHART, MAJOR INCLUSION & EXCLUSION CRITERIA**

**Major Inclusion Criteria**
- 18 years of age or older;
- Must have metastatic, recurrent, or persistent cervical cancer not amenable to curative surgery or radiation;
- Must have at least 1 lesion resectable for TIL generation that yields at least 1.5 cm in diameter of tissue. If previously irradiated, the irradiation must have occurred at least 3 months prior to enrollment;
- Must have a remaining lesion measurable as per RECIST 1.1 for response assessment. If previously irradiated, the irradiation must have occurred at least 3 months prior to enrollment (tumor resection);
- Must have received at least 1 line of prior systemic therapy for their metastatic or persistent cervical cancer;
- Minimum 28 day washout from last dose of tumor-directed therapy to tumor resection;
- ECOG performance status of 0 or 1;
- Adequate bone marrow, liver, and renal function;
- HIV negative;
- Negative or undetectable for Hepatitis B and Hepatitis C;
- Up to 1 year of birth control following completion of study treatment.

**Major Exclusion Criteria**
- Prior cell therapy;
- Systemic steroid therapy greater than 10mg daily equivalent of prednisone;
- Must have grade 1 prior treatment-related toxicities except for peripheral neuropathy, alopecia, or vitiligo;
- Active immunotherapy-related grade 2 or higher toxicities or co morbidity in the prior 6 months; patients may be included if asymptomatic and demonstrated unaffected colon by colonoscopy;
- Active untreated infections, coagulation disorders, or other active major medical illnesses of the cardiovascular, respiratory or immune system that, in the opinion of the investigator, would increase the risk of participation;
- Symptomatic and/or untreated brain metastases;
- Primary or acquired immunodeficiency;
- End-stage renal disease requiring dialysis;
- Left ventricular ejection fraction < 45%:
- Forced expiratory volume in one second ≤ 60% predicted;
- Primary malignancy in the previous 3 years requiring treatment in the last year; and
- Pregnant or breastfeeding.

**DISCLOSURE**

This study and poster are sponsored by Iovance Biotherapeutics, Inc.